General Information of Drug Combination (ID: DCXN3C2)

Drug Combination Name
ETHISTERONE Diethylcarbamazine
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs ETHISTERONE   DMDXRP1 Diethylcarbamazine   DM1TJ8F
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 27.21
Bliss Independence Score: 27.21
Loewe Additivity Score: 38.51
LHighest Single Agent (HSA) Score: 38.51

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of ETHISTERONE
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [2]
ETHISTERONE Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tyrosinase (TYR) TTULVH8 TYRO_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
ETHISTERONE Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Serine/threonine-protein kinase Sgk1 (SGK1) OT301T1U SGK1_HUMAN Increases Expression [5]
Myb-related protein A (MYBL1) OTBJMC2P MYBA_HUMAN Increases Expression [5]
Protein GREB1 (GREB1) OTU6ZA26 GREB1_HUMAN Increases Expression [5]
------------------------------------------------------------------------------------
Indication(s) of Diethylcarbamazine
Disease Entry ICD 11 Status REF
Elephantiasis N.A. Approved [3]
Loiasis N.A. Approved [3]
Lymphatic filariasis 1F66.3 Approved [4]
Onchocerciasis 1F6A Approved [3]
Diethylcarbamazine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Arachidonate 5-lipoxygenase (5-LOX) TT2J34L LOX5_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
Diethylcarbamazine Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Increases Activity [7]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 TOMOCOMD-CARDD descriptors-based virtual screening of tyrosinase inhibitors: evaluation of different classification model combinations using bond-b... Bioorg Med Chem. 2007 Feb 1;15(3):1483-503.
3 Diethylcarbamazine FDA Label
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 A Gene Expression Biomarker Identifies Chemical Modulators of Estrogen Receptor in an MCF-7 Microarray Compendium. Chem Res Toxicol. 2021 Feb 15;34(2):313-329. doi: 10.1021/acs.chemrestox.0c00243. Epub 2021 Jan 6.
6 Inhibition of leukotriene formation by diethylcarbamazine modifies the acid-base balance in the rabbits with blast injuries of the lungs. Vojnosanit Pregl. 1999 May-Jun;56(3):243-7.
7 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.